Skip to main content
Following the recent approval of lifileucel for unresectable or metastatic melanoma—the first cellular therapy to receive an approval for solid tumors—Matthew Hadfield, DO, member of the Oncology Data Advisor Fellows Forum and third-year Fellow at Br...
On Rare Disease Day on February 29, members of the Oncology Data Advisor Editorial Board and Fellows Forum hosted a live panel discussion focused on the rare diseases that they treat, including tireless efforts underway to develop novel treatment str...
In honor of World Cancer Day on February 4, members of the Oncology Data Advisor Fellows Forum and Editorial Board joined forces for a thought-provoking discussion about improving cancer care on a global scale, including treatment access, molecular t...
Oncology Data Advisor® · Thirty Years in the Making: The Approval of Lifileucel for Metastatic Melanoma Following the recent approval of lifileucel for unresectable or metastatic melanoma—the first cellular therapy to receive an approval f...
Oncology Data Advisor® · World Cancer Research Day With Samuel Kareff, Maria Badillo, Matthew Hadfield, and Alankrita Taneja In honor of World Cancer Research Day, members of Oncology Data Advisor's Editorial Board and Fellows Forum joined...
Oncology Data Advisor® · Melphalan for Liver-Directed Treatment of Uveal Melanoma With Richard Carvajal, MD Recently, the FDA approved melphalan for liver-directed treatment of uveal melanoma. In this interview, Oncology Data Advisor Edito...
By Waqas Haque, MD, MPH In this latest edition of The Way Ahead: The Convergence of Technology and Cancer Care, Dr. Waqas Haque shares his perspectives on the approval of lifileucel, the first individualized tumor-infiltrating lymphocyte therapy, for...
The FDA has granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) for adult patients with unresectable or metastatic melanoma previously treated with a programmed cell death protein 1 (PD-1) blocking antibody, and if BRA...
The FDA has approved nivolumab (Opdivo®, Bristol Myers Squibb Company) for adjuvant treatment of patients 12 and older with completely resected stage IIB/C melanoma.   Why it matters: "Patients with resected stage IIB/C melanoma are at high risk...